Seres Therapeutics, Inc.
MCRB
$19.44
$1.126.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.60% | 181.43% | 62.09% | 285.51% | -170.61% |
| Total Depreciation and Amortization | -25.42% | -30.98% | -2.35% | -16.63% | -7.01% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | 17.81% | 223.33% |
| Total Other Non-Cash Items | -43.47% | -59.55% | -88.80% | -1,343.21% | -59.46% |
| Change in Net Operating Assets | 106.63% | -27.96% | -95.76% | 57.90% | -1,036.41% |
| Cash from Operations | 66.62% | 176.37% | 18.14% | 41.47% | -160.33% |
| Capital Expenditure | -82.83% | 45.16% | 89.74% | 92.82% | 91.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -88.08% |
| Cash from Investing | -113.90% | 45.16% | 89.74% | 7,954.37% | -87.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -93.71% | -72.98% | 1,080.46% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -93.71% | -72.98% | -7,783.37% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 65.02% | 269.67% | 11.23% | 92.61% | -128.59% |